NCT03754660View on ClinicalTrials.gov

This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 21, 2019

Primary Completion Date

April 24, 2022

Study Completion Date

November 3, 2022

Conditions
Hypertension, Pulmonary
Interventions
DRUG

BAY1237592

Oral inhalation with dry powder inhaler, single dose.

Trial Locations (8)

8036

Medizinische Universität Graz, Graz

12808

Vseobecna fakultni nemocnice v Praze, Prague

35392

Universitätsklinikum Giessen und Marburg, Giessen

80639

Krankenhaus Neuwittelsbach, München

93042

Universitätsklinikum Regensburg, Regensburg

140 21

Institut Klinicke a Experimentalni Mediciny, Prague

01307

Universitätsklinikum Carl Gustav Carus Dresden, Dresden

31-202

Szpital Specjalistyczny im. Jana Pawla II, Krakow

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT03754660 - This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) | Biotech Hunter | Biotech Hunter